(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.32%.
Lexeo Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LXEO's revenue for 2024 to be $148,774,518, with the lowest LXEO revenue forecast at $148,774,518, and the highest LXEO revenue forecast at $148,774,518. On average, 1 Wall Street analysts forecast LXEO's revenue for 2025 to be $148,774,518, with the lowest LXEO revenue forecast at $148,774,518, and the highest LXEO revenue forecast at $148,774,518.
In 2027, LXEO is forecast to generate $1,561,140,609 in revenue, with the lowest revenue forecast at $1,561,140,609 and the highest revenue forecast at $1,561,140,609.